- Home
- LFT vs CING Comparison
LFT vs CING Comparison
Compare LFT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | CING |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 59.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFT | CING |
|---|---|---|
| Price | $0.93 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 214.2K | ★ 355.4K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $668.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $3.16 |
| 52 Week High | $2.45 | $11.89 |
Technical Indicators
Market Signals| Indicator | LFT | CING |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 43.64 |
| Support Level | N/A | $4.20 |
| Resistance Level | $1.40 | $5.30 |
| Average True Range (ATR) | 0.05 | 0.37 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 12.32 | 7.17 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.